American Association for Cancer Research
Browse

Table S1 and S2 from T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers

Download (106.27 kB)
dataset
posted on 2023-03-31, 20:40 authored by Drew C. Deniger, Anna Pasetto, Paul F. Robbins, Jared J. Gartner, Todd D. Prickett, Biman C. Paria, Parisa Malekzadeh, Li Jia, Rami Yossef, Michelle M. Langhan, John R. Wunderlich, David N. Danforth, Robert P.T. Somerville, Steven A. Rosenberg

Clinical details (S1) and neoepitope details (S2).

Funding

National Natural Science Foundation of China

Key Clinical Specialty Discipline Construction Program

National Key Research and Development Program of China

Natural Science Foundation of Guangdong Province

Science and Technology Planning Project of Guangzhou

Director's Foundation of Nanfang Hospital

History

ARTICLE ABSTRACT

Purpose: This was a study prospectively evaluating intratumoral T-cell responses to autologous somatic mutated neoepitopes expressed by human metastatic ovarian cancers.Patients and Methods: Tumor-infiltrating lymphocytes (TIL) were expanded from resected ovarian cancer metastases, which were analyzed by whole-exome and transcriptome sequencing to identify autologous somatic mutations. All mutated neoepitopes, independent of prediction algorithms, were expressed in autologous antigen-presenting cells and then cocultured with TIL fragment cultures. Secretion of IFNγ or upregulation of 41BB indicated a T-cell response.Results: Seven women with metastatic ovarian cancer were evaluated, and 5 patients had clear, dominant T-cell responses to mutated neoantigens, which were corroborated by comparison with the wild-type sequence, identification of the minimal epitope, human leukocyte antigen (HLA) restriction element(s), and neoantigen-specific T-cell receptor(s). Mutated neoantigens were restricted by HLA-B, -C, -DP, -DQ, and/or -DR alleles and appeared to principally arise from random, somatic mutations unique to each patient. We established that TP53 “hotspot” mutations (c.659A>G; p.Y220C and c.733G>A; p.G245S) expressed by two different patients' tumors were both immunogenic in the context of HLA-DRB3*02:02.Conclusions: Mutation-reactive T cells infiltrated ovarian cancer metastases at sufficient frequencies to warrant their investigation as adoptive cell therapy. In addition, transfer of TP53 “hotspot” mutation-reactive T-cell receptors into peripheral blood T cells could be evaluated as a gene therapy for a diverse range of tumor histologies. Clin Cancer Res; 24(22); 5562–73. ©2018 AACR.See related commentary by McNeish, p. 5493